亞盛醫藥-B(06855.HK):Bcl-2抑制劑APG-2575治療中國復發╱ 難治性非霍奇金淋巴瘤患者最新臨牀進展將在EHA 2022上公佈
格隆匯5月23日丨亞盛醫藥-B(06855.HK)發佈公吿,公司將在2022年歐洲血液學協會年會(EHA 2022)上公佈在研原創1類新藥Bcl-2選擇性抑制劑APG-2575治療中國的復發╱難治性非霍奇金淋巴瘤(r/r NHLs)患者的I期臨牀試驗的最新臨牀結果。這也是亞盛醫藥在歐洲血液學協會年會的首次亮相。
歐洲血液學協會(EHA)年會作為歐洲血液學領域規模最大的國際會議,每年吸引來自全球100多個國家的1萬多名專業人士與會,分享全球最前沿的研究進展和突破性臨牀數據。本屆EHA年會將於2022年6月9日至2022年6月12日在奧地利維也納以“線上+線下”相結合的方式召開。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.